NCT07465588: REINFORCE

Financial Rewards for Reducing Alcohol Use in Patients With Liver Disease

Not yet recruiting NA Last updated 12 March 2026

What this trial tests

NA trial testing PEth Based Contingency Management in Alcohol Use Disorder in 90 participants. Not yet recruiting.

Timeline

1 August 2026

Primary endpoint
31 March 2028

30 June 2028

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	1 August 2026
Primary completion	31 March 2028
Estimated completion	30 June 2028

Drugs / interventions tested

• PEth Based Contingency Management
• PEth Monitoring with Fixed Incentives

Conditions studied

• Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
• Alcohol-associated Liver Disease — all drugs for Alcohol-associated Liver Disease →
• Liver Cirrhosis, Alcoholic — all drugs for Liver Cirrhosis, Alcoholic →
• Alcohol-Associated Hepatitis — all drugs for Alcohol-Associated Hepatitis →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Alcohol Use Disorder or Alcohol-associated Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study tests whether providing financial rewards based on a blood test result can help people with alcohol-associated liver disease (ALD) stop or reduce their drinking. The blood test is called phosphatidylethanol (PEth), which can detect alcohol use over the past three to four weeks. The financial reward program is called contingency management (CM).

The study has two parts. Part 1 involves one-time interviews and surveys with patients and healthcare providers to understand how a PEth-based CM program could best be delivered in a liver disease clinic. Part 2 is a pilot randomized controlled trial (the REINFORCE Trial) in which participants are randomly assigned to one of two groups: (1) a rewards group that receives escalating financial incentives when PEth results show reduced or no alcohol use, or (2) a monitoring group that receives fixed payments regardless of PEth results. Both groups receive PEth testing and continue their usual medical care. The study will assess whether the rewards program improves alcohol abstinence and reduction at 12 and 24 weeks.'

Publications & conference data

No peer-reviewed publications indexed yet for this trial.